Jason Lebowitz,1 Christopher A. Scheiner,2 Samir P. Macwan,3 Nicholas Streicher,4 Karen S. Yee,5 Chloe Sader,5 Michael Blackowicz,5 Nana Numapau,5 Danielle Gentile,6 Jason Sharpe,6 Prathamesh Pathak,6 Michael T. Pulley7
1 Alexion Medical Affairs
2 University of Tennessee Medical Center, Knoxville, TN
3 Eisenhower Health Center, Rancho Mirage, CA
4 MedStar Georgetown University Hospital
5 Alexion, AstraZeneca Rare Disease, Boston, MA
6 Cardinal Health, Dublin, OH
7 University of Florida College of Medicine, Jacksonville, FL
Targeted therapies such as ravulizumab and efgartigimod are approved to treat AChR-Ab+ gMG. However, there is a lack of real-world data assessing clinical outcomes among patients treated with these therapies. Physician-abstracted EMRs included for adults with AChR-Ab+ gMG in Cardinal Health’s Neurology Provider Extended Network who initiated their first targeted immunotherapy on or after Dec 1, 2021. Outcomes included clinical characteristics, concomitant medication use, and MG-ADL total scores up to 2 years preinitiation and after treatment initiation with additional efficacy measures. Data were available for 152 patients. Mean±SD age at initiation was 61.5±13.6 years for the ravulizumab group and 57.0±16.6 for the efgartigimod group. Preinitiation, mean±SD MG-ADL total scores were 9.3±2.9 in the ravulizumab group and 8.7±3.8 in the efgartigimod group. Mean±SD MG-ADL total scores at 3 mo. post initiation were 4.7±3.1 and 5.6±3.4 with ravulizumab and efgartigimod, respectively, and at 6 mo. post initiation, total scores were 2.0±1.8 and 4.3±3.2, respectively. Despite varying pt. characteristics, both treatments improved outcomes and decreased OCS dosing. Pts. who received ravulizumab trended toward greater improvements in MG-ADL total score than those who received efgartigimod.
